MRK vs. NVO
Compare and contrast key facts about Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MRK or NVO.
Correlation
The correlation between MRK and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
MRK vs. NVO - Performance Comparison
Key characteristics
MRK:
-1.34
NVO:
-1.18
MRK:
-1.78
NVO:
-1.72
MRK:
0.76
NVO:
0.77
MRK:
-0.87
NVO:
-0.86
MRK:
-1.65
NVO:
-1.74
MRK:
19.22%
NVO:
26.39%
MRK:
23.69%
NVO:
38.77%
MRK:
-68.62%
NVO:
-71.29%
MRK:
-33.50%
NVO:
-53.42%
Fundamentals
MRK:
$218.22B
NVO:
$296.36B
MRK:
$6.74
NVO:
$3.27
MRK:
12.82
NVO:
20.52
MRK:
0.79
NVO:
1.04
MRK:
$48.39B
NVO:
$225.05B
MRK:
$39.64B
NVO:
$190.45B
MRK:
$19.98B
NVO:
$113.24B
Returns By Period
In the year-to-date period, MRK achieves a -12.41% return, which is significantly higher than NVO's -20.74% return. Over the past 10 years, MRK has underperformed NVO with an annualized return of 7.97%, while NVO has yielded a comparatively higher 11.49% annualized return.
MRK
-12.41%
-5.86%
-20.28%
-31.52%
6.74%
7.97%
NVO
-20.74%
-22.08%
-40.75%
-46.11%
19.54%
11.49%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MRK vs. NVO — Risk-Adjusted Performance Rank
MRK
NVO
MRK vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
MRK vs. NVO - Dividend Comparison
MRK's dividend yield for the trailing twelve months is around 3.66%, more than NVO's 2.40% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 3.66% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
NVO Novo Nordisk A/S | 2.40% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
MRK vs. NVO - Drawdown Comparison
The maximum MRK drawdown since its inception was -68.62%, roughly equal to the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for MRK and NVO. For additional features, visit the drawdowns tool.
Volatility
MRK vs. NVO - Volatility Comparison
The current volatility for Merck & Co., Inc. (MRK) is 7.09%, while Novo Nordisk A/S (NVO) has a volatility of 12.78%. This indicates that MRK experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
MRK vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Merck & Co., Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities